TITLE

New drug is approved in kidney cancer fight

AUTHOR(S)
Bill Caven
PUB. DATE
November 2013
SOURCE
Daily Mail;11/12/2013, p19
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
PATIENTS fighting kidney cancer in Scotland are to benefit for the first time from a new drug.
ACCESSION #
91908117

 

Related Articles

  • No Cure for Cancer? Wall Street Waits - and Hesitates. O'Connell, Brian // BioPharm International;Sep2005, Vol. 18 Issue 9, p18 

    Reports on the issues surrounding the development of drugs to treat cancer by pharmaceutical companies in the U.S. Search of Pfizer Inc. for a regulatory approval for its new drug Sutent that targets stomach and kidney cancers; Provision of conditional approval to the new cancer drug by the Food...

  • 'THE FUTURE OF CANCER TREATMENT' O'Keefe, Brian // Fortune;7/23/2001, Vol. 144 Issue 2, p80 

    Discusses the outlook for the treatment of cancer. Outlook for the success of Novartis in fighting cancer, in light of the approval of the drug Gleevec; Outlook for the development of drugs to fight the disease; Approval of drugs by the United States Food and Drug Administration.

  • Targeted RCC therapies create new role for urologists. Uzzo, Robert G. // Urology Times;9/1/2006, Vol. 34 Issue 11, p1 

    This article presents an interview with Physician Robert Uzzo, an attending surgeon at Fox Chase Cancer Center's department of urologic oncology in Philadelphia, Pennsylvania. Uzzo discusses new kidney cancer drugs and their potential impact on urologists' approach to the disease. He gives his...

  • GlaxoSmithKline wins FDA approval for kidney cancer drug.  // PharmaWatch: Cancer;Dec2009, Vol. 8 Issue 12, p13 

    The article presents information on the U.S. Food & Drug Administration's (FDA) approval of a kidney cancer drug developed by GlaxoSmithKline. The drug helps treat patients with advanced renal cell carcinoma (RCC). The company mentions that the drug prevents the growth of new blood vessels and...

  • Wyeth's Torisel gets European approval in kidney cancer.  // PharmaWatch: Biotechnology;Jan2008, Vol. 7 Issue 1, p13 

    The article reports on the approval of Wyeth's Torisel by the European Commission as a first-line treatment of patients with advanced renal cell carcinoma. The Commission's approval of the drug emphasizes its importance for advanced treatment of kidney cancer and reinforces the potential of its...

  • Taxol: Search for a cancer drug. Joyce, Christopher // BioScience;Mar1993, Vol. 43 Issue 3, p133 

    Describes the benefits of the natural drug, taxol, on the fight against cancer. The Food and Drug Administration (FDA) has approved the drug for general use in advanced ovarian cancer. Taxol was discovered in 1963; Where taxol stands now; How taxol attacks cancer; Conservation concerns for the...

  • Agrohimichesko Obsluzhvane OOD.  // SeeNews Research & Profiles (Company Profiles);2011, Special section p1 

    A profile of Agrohimichesko Obsluzhvane OOD, also known as Agrochimechesko Obsluzhvane Ltd., Agrochemical Service OOD, and Agrochemical Service Ltd., is presented. The company is based in Bulgaria and provides agrochemical services. Milka Genova Valkova is the chief executive officer (CEO) of...

  • New Drug for Advanced Liver Cancer Increases Survival. McBride, Deborah // ONS Connect;Nov2007, Vol. 22 Issue 11, p6 

    The article reports on a study which found that the new drug sorafenib has improved the survival of advanced liver cancer patients. The drug, with a trade name of Nexavar, is established by experts to be the standard treatment for advanced liver cancer as no drug treatments for the disease...

  • Advances in kidney cancer therapy. Rosenberg, Jonathan; Small, Eric J. // Urology Times;Mar2008, Vol. 36 Issue 3, ps10 

    The article reports on the advances in kidney cancer therapy in the U.S. It states that immunotherapy is the standard treatment for metastatic kidney cancer. It adds that the Food and Drug Administration approved high-dose interleukin-2 for the treatment of advanced kidney cancer because of its...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics